This kit is designed for the detection of binding activity between Human EGF and EGFR using a homogeneous LANCE Ultra TR-FRET assay. This assay can facilitate the design and development of therapeutics which competitively inhibit EGF/EGFR interaction.
For research use only. Not for use in diagnostic procedures. All products to be used in accordance with applicable laws and regulations including without limitation, consumption and disposal requirements under European REACH regulations (EC 1907/2006).
Feature | Specification |
---|---|
Application | Protein-Protein Interaction |
Sample Volume | 5 µL |
This kit is designed for the detection of binding activity between Human EGF and EGFR using a homogeneous LANCE Ultra TR-FRET assay. This assay can facilitate the design and development of therapeutics which competitively inhibit EGF/EGFR interaction.
For research use only. Not for use in diagnostic procedures. All products to be used in accordance with applicable laws and regulations including without limitation, consumption and disposal requirements under European REACH regulations (EC 1907/2006).
LANCE® and LANCE® (Lanthanide chelate excite) Ultra are our TR-FRET (time-resolved fluorescence resonance energy transfer), homogeneous (no wash) technologies. Streptavidin is labeled with a donor fluorophore (a LANCE Europium chelate) which binds to biotinylated EGF and the EGFR-Fc is recognized by anti-human IgG labeled with an acceptor fluorophore [ULight™ dye]. Upon excitation at 320 or 340 nm, energy can be transferred from the donor Europium chelate to the acceptor fluorophore if sufficiently close for FRET (~10 nm). This results in the emission of light at 665 nm.
Epidermal Growth Factor Receptor (EGFR, Her1, ErbB1) is a 134 kDa cell surface receptor, part of a four member subfamily of receptor tyrosine kinases (erbB1, erbB2, erbB3, and erbB4). EGFR binds to a family of proteins called the epidermal growth factors (primarily EGF), which, upon association induces dimerization of the receptor and initiates signal transduction for the promotion of cell survival and growth. Mutations that cause aberrant overexpression of EGF and/or EGFR have been linked with many different cancers such as non-small-cell lung and colon cancers. Drugs are being developed as a means to better treat these types cancer.
Application |
Protein-Protein Interaction
|
---|---|
Automation Compatible |
Yes
|
Brand |
LANCE Ultra
|
Detection Modality |
LANCE
|
Product Group |
Kit
|
Sample Volume |
5 µL
|
Shipping Conditions |
Shipped in Blue Ice
|
Target |
EGF,EGFR
|
Target Class |
Binding Assay
|
Target Species |
Human
|
Technology |
TR-FRET
|
Therapeutic Area |
Oncology
|
Unit Size |
10,000 Assay Points
|
Are you looking for resources, click on the resource type to explore further.
LANCE™ Ultra TR-FRET is a no-wash proximity assay technology that combines the benefits of time resolution (TR) with fluorescence...
We are here to answer your questions.